ACADEMIC BIO

  • B.S., 1962, Idaho State University
  • Ph.D., 1965, University of Kansas

RESEARCH OVERVIEW

Research activities are concerned with chemical aspects of drug metabolism and drug action from mechanistic and stereochemical viewpoints. Many drugs are used as racemic mixtures in which the optical isomers (enantiomers) have different pharmacological or toxicological properties, as well as different rates or pathways of metabolism. We are particularly interested in exploring pathways of the metabolism of cardiovascular drugs, agents widely used for the treatment of hypertension and other diseases. Among these are the β-adrenergic blocking agents and calcium channel antagonists. We have prepared enantiomers labeled specifically with deuterium or 13C, and we are studying the metabolism of the compounds as pseudoracemates (equimolar mixtures of the enantiomers in which only one of the enantiomers is labeled). A number of putative metabolites are synthesized to confirm their identity. Expected intermediates in metabolic processes and diastereomeric metabolites of known stereochemistry are synthesized, identified and quantitated. In this way, we can examine the metabolic pathways for their formation to obtain an understanding of how the drugs are metabolized.

Ongoing work with others includes the synthesis and purification of metabolites and potential metabolic intermediates for studies related to the formation of metabolic inhibitor complexes that occur in the metabolism of secondary and tertiary amine drugs, e.g., synthesis of hydroxylamines, nitrones, and nitroso compounds. Among the drugs under study are imipramine, fluoxetine, and fluvoxamine, tamoxifen, and diltiazem. Work on obtaining metabolites of retinoic acid, especially hydroxylated regioisomers, is also under way.


RECENT SELECTED PUBLICATIONS

  • Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zeiter A, Thatcher JE, Nelson WL and Isoherranen N. "Expression and Functional Characterization of Cytochrome P450 26A1, a Retinoic Acid Hydroxylase." Biochem Pharmacol. 77:258-268 (2009).

  • Templeton I, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL and Isoherranen N. "Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 in Vivo." Clinical Pharmacol. Ther. 83:77-85 (2008).

  • Nelson WL. "Chapter 37. Antihistamines and Related Anti-allergic and Anti-ulcer Agents." Principles of Medicinal Chemistry, 6th Edition, Williams DA and Lemke TL, Ed., 1004-1027 (2007).

  • Kunze KL, Nelson WL, Thummel KE, Kharasch ED and Isoherranen N. "Stereoselective Metabolism of Itraconazole in Vitro and in Vivo." Drug Metab Dispos. 34:583-590 (2006).

  • Upthagrove AL and Nelson WL. "Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Analogs. Preparation, Identification of Metabolite Regioisomers and Metabolism by CYP2D6." Drug Metab Dispos. 29:1377-1388 (2001).

  • Upthagrove AL and Nelson WL. "Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propanolol Analogs. Metabolism by CYP1A2." Drug Metab Dispos. 29:1389-1395 (2001).

 


Medicinal Chemistry Home
|| Mass Spectrometry Center
School of Pharmacy Home || Department of Pharmaceutics || Department of Pharmacy

Last updated:  
©2003-2009 University of Washington School of Pharmacy